Black Rock Inc. Surface Oncology, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.57 - $0.88 $97,009 - $149,768	-170,192 Reduced 24.63%	520,886 $453,000
Q1 2023 May 12, 2023	BUY	$0.61 - $1.03 $8,340 - $14,083	13,673 Added 2.02%	691,078 $483,000
Q4 2022 Feb 13, 2023	SELL	$0.62 - $1.21 $216,567 - $422,655	-349,302 Reduced 34.02%	677,405 $555,000
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.1 $6,639 - $13,278	-6,323 Reduced 0.61%	1,026,707 $1.07 Million
Q2 2022 Aug 12, 2022	SELL	$1.42 - $3.15 $2.15 Million - $4.77 Million	-1,515,075 Reduced 59.46%	1,033,030 $1.69 Million
Q1 2022 May 12, 2022	SELL	$2.65 - $5.08 $38,637 - $74,066	-14,580 Reduced 0.57%	2,548,105 $7.49 Million
Q4 2021 Feb 10, 2022	BUY	$4.73 - $7.9 $651,519 - $1.09 Million	137,742 Added 5.68%	2,562,685 $12.3 Million
Q3 2021 Nov 09, 2021	SELL	$5.16 - $7.98 $619,148 - $957,520	-119,990 Reduced 4.71%	2,424,943 $18.4 Million
Q2 2021 Aug 11, 2021	BUY	$6.45 - $9.09 $16.4 Million - $23.1 Million	2,544,933 New	2,544,933 $19 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.